There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.
The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...
Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted ...
Hims & Hers Health, Inc. could see more upside in partnerships and international expansion. Click here to read an analysis of ...
23h
The next-generation weight loss drug that’s ‘as effective as Mounjaro – WITHOUT Ozempic side effect’
A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly ...
TEENAGE boys aren’t famous for expressing their feelings. But as my son Jeremiah sweeps me up into a hug and thanks me, I ...
Donald Trump hailed his deal to slash the price of blockbuster weight loss drugs as a game changer. But major gaps in the ...
Dr. Oz estimated Americans could lose "135 billion pounds" by the midterm elections next year. The administrator of the ...
The guidance describes obese foreigners as a ‘public charge’ and orders visa officers to guess how much they would claim in ...
Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up ...
The White House is expected to announce a deal for lower prices of obesity drugs from Novo Nordisk and Eli Lilly on Thursday ...
Mounjaro, the breakthrough obesity and diabetes drug from Eli Lilly and Company, has become India’s highest-selling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback